AVITA Medical (AVH) Stock Price, News & Analysis

Company Overview

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 27.28 million shs
• Average Volume: N/A
• Market Capitalization: A$226.55 million
• P/E Ratio: N/A
• Dividend Yield: 0.30%
• Price Target: N/A
• Consensus Rating: N/A

AVH Stock Analysis - Frequently Asked Questions

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (ASX:AVH) issued its quarterly earnings results on Thursday, February, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. AVITA Medical had a negative trailing twelve-month return on equity of 39.79% and a negative net margin of 77.47%.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AVITA Medical investors own include AVITA MED LTD/S (AVMXY), Avita Medical (RCEL), Boundless Bio (BOLD), Northern Dynasty Minerals (NAK), Orchid Island Capital (ORC), 88 Energy (88E) and Magellan Financial Group (MFG).

Company Calendar

• Last Earnings: 2/28/2019
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Electronic Equipment
• Current Symbol: ASX:AVH
• CIK: N/A
• Web: www.avitamedical.com
• Phone: 661-367-9170
• Fax: N/A
• Employees: 207
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$49.83 million
• Net Margins: -77.47%
• Pretax Margin: N/A
• Return on Equity: -39.79%
• Return on Assets: -38.98%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 8.18
• Quick Ratio: 9.32

Sales & Book Value

• Annual Sales: A$54.14 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 8.47
• Book Value: A$1.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 129,950,000
• Free Float: N/A
• Market Cap: A$226.55 million
• Optionable: Not Optionable
• Beta: 1.54